Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1
  • Main
  • Сlinical Trials
    • Completed phase I/IIa clinical trial
    • Case studies
    • Ex-US Clinical Trials
    • US clinical trials
  • Dogs & Cats
    • Comparative Medicine and Veterinary Research
  • Elenagen
    • Elenagen is a Plasmid (Circular DNA) Encoding Gene P62/SQSTM1
    • Elenagen Reduces/Reverts Tumor Grade
    • Elenagen Changes Tumor Microenvironment
    • Elenagen Downregulates Chronic Inflammation
    • Elenagen Enhances Anti-Tumoral Immune Response
  • IP
  • Publications
  • Investors
    • One-pager
    • Slide presentation
  • Team
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Careers
  • News
    • Company news
    • In the news
  • Legal
CureLab Oncology and the American Eurasian Cancer Alliance Partner to Fight Ovarian Cancer
January 31, 2022
University of Camerino Signs Strategic Partnership with CureLab Veterinary to Revolutionize Cancer Treatment for Companion Animals
April 22, 2022
March 30, 2022
TheScientist-Russia

The Scientist: Russian Scientists Grapple with an Uncertain Future

TheScientist-Russia

As the terrible Ukraine-Russia situation evolves, what does this portend for scientists located in the region? Scientists from countries with differing political systems have long collaborated with colleagues located in politically distressed and war-torn regions. Despite the associated challenges, these collaborations have combined their respective strengths and even leveraged the unique characteristics of their regional differences.

For example, in the case of our CureLab science team, some of our scientists—many of whom have roots in Eastern Europe—have been focused on advancing science and medicine without regard for politics. In fact, by conducting clinical research in Eastern Europe, we can take advantage of the region’s epidemiological genetic characteristics to speed progress of our clinical trials.

But these collaborations have in some cases been placed under immense stress. As one journalist notes, “Once Russia’s military invasion of Ukraine got underway, changes in policies and severances of international scientific collaborations with Russian universities and researchers have become apparent. The war has also precipitated a moral reckoning for many scientists in Russia.”

The Scientist just published an in-depth feature story on this subject, written by freelance journalist Anna Azvolinsky.

CureLab’s CEO Dr. Alex Shneider was : interviewed for the story:

Alexander Shneider, the founder and CEO of Boston-based CureLab Oncology, advocates for providing Russian scientists with a path out of the country if that’s what they want. The company has been collaborating with Russian, Belarussian, and Ukrainian scientists and clinicians for 20 years, Shneider says, and he’s witnessed the current crisis unfold through the personal stories of those on both sides of the war’s borders. “There are no simple conclusions here or remedies to solve this complex problem” of the predicaments these scientists find themselves in, he says.

For the past four weeks, Shneider says, he begins his day with calls and text messages checking in on the safety of his Ukrainian colleagues and on Russian researchers he used to collaborate with through CureLab. For those Ukrainian scientists who are relatively out of harm’s way, the best way to help them is to give them remote contract work as soon as possible so they can support themselves and their families, he says. Some excellent Russian scientists who have left the country for Armenia, Georgia, or other countries “deserve as much help as Ukrainian scientists,” Shneider says. “Most have no means for an income, and Western countries need to provide them with jobs as soon as possible before they fall into wrong hands… …A scientist anywhere in the world should feel that if he disagrees with a regime, he would be welcome elsewhere based on his professional skills.”

Himself an immigrant from the former Soviet Union with Russian and Ukrainian roots, Shneider says he also understands those like Irina who have decided to stay and resist their government via the education of their children, closed-door conversations, and other means. “If all honorable Russian people leave, who would be our future allies there?” says Shneider.

The entire article can be found here.

Share

Related posts

May 3, 2022

CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in South Korea


Read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

  • The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
  • The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
  • We are now preparing Phase II Clinical Trials within the US.

Contact us

E-mail:

info@curelab.com,

Call us:

1-609-841-1201

177 HUNTINGTON
AVE FL 17
BOSTON MA 02115-3156
© 2020 CureLab Oncology.